Human neural stem cell transplantation in ALS: initial results from a phase I trial

Letizia Mazzini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Maurizio Gelati, Daniela Celeste Profico, Giada Sgaravizzi, Massimo Projetti Pensi, Gianmarco Muzi, Claudia Ricciolini, Laura Rota Nodari(Istituti di Ricovero e Cura a Carattere Scientifico), Sandro Carletti(Santa Maria Nuova Hospital), Cesare Giorgi(Santa Maria Nuova Hospital), Cristina Spera(Santa Maria Nuova Hospital), Domenico Frondizi(Santa Maria Nuova Hospital), Enrica Bersano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), F. Petruzzelli(Casa Sollievo della Sofferenza), Carlo Cisari(Azienda Ospedaliero Universitaria Maggiore della Carita), Annamaria Maglione(Casa Sollievo della Sofferenza), Maria Francesca Sarnelli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alessandro Stecco, Giorgia Querin(University of Padua), Stefano Masiero(University of Padua), Roberto Cantello(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Daniela Ferrari(University of Milano-Bicocca), Cristina Zalfa(University of Milano-Bicocca), Elena Binda(Istituti di Ricovero e Cura a Carattere Scientifico), Alberto Visioli(University of Milano-Bicocca), Domenico Trombetta(Istituti di Ricovero e Cura a Carattere Scientifico), Antonio Novelli(Istituti di Ricovero e Cura a Carattere Scientifico), Bárbara Torres(Casa Sollievo della Sofferenza), Laura Bernardini(Istituti di Ricovero e Cura a Carattere Scientifico), Alessandro Carriero, Paolo Prandi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Serena Servo(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Annalisa Cerino(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Valentina Cima(University of Padua), Alessandra Gaiani(University of Padua), Nicola Nasuelli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Maurilio Massara(Azienda Ospedaliero Universitaria Maggiore della Carita), Jonathan D. Glass(Emory University), Gianni Sorarú(University of Padua), Nicholas M. Boulis(Emory University), Angelo L. Vescovi(ASM Terni (Italy))
Journal of Translational Medicine
January 1, 2015
Cited by 204Open Access
Full Text

Abstract

BACKGROUND: We report the initial results from a phase I clinical trial for ALS. We transplanted GMP-grade, fetal human neural stem cells from natural in utero death (hNSCs) into the anterior horns of the spinal cord to test for the safety of both cells and neurosurgical procedures in these patients. The trial was approved by the Istituto Superiore di Sanità and the competent Ethics Committees and was monitored by an external Safety Board. METHODS: Six non-ambulatory patients were treated. Three of them received 3 unilateral hNSCs microinjections into the lumbar cord tract, while the remaining ones received bilateral (n = 3 + 3) microinjections. None manifested severe adverse events related to the treatment, even though nearly 5 times more cells were injected in the patients receiving bilateral implants and a much milder immune-suppression regimen was used as compared to previous trials. RESULTS: No increase of disease progression due to the treatment was observed for up to18 months after surgery. Rather, two patients showed a transitory improvement of the subscore ambulation on the ALS-FRS-R scale (from 1 to 2). A third patient showed improvement of the MRC score for tibialis anterior, which persisted for as long as 7 months. The latter and two additional patients refused PEG and invasive ventilation and died 8 months after surgery due to the progression of respiratory failure. The autopsies confirmed that this was related to the evolution of the disease. CONCLUSIONS: We describe a safe cell therapy approach that will allow for the treatment of larger pools of patients for later-phase ALS clinical trials, while warranting good reproducibility. These can now be carried out under more standardized conditions, based on a more homogenous repertoire of clinical grade hNSCs. The use of brain tissue from natural miscarriages eliminates the ethical concerns that may arise from the use of fetal material. TRIAL REGISTRATION: EudraCT:2009-014484-39 .


Related Papers

No related papers found

Powered by citation graph analysis